What is Zacks Research’s Estimate for Medifast Q2 Earnings?

Medifast, Inc. (NYSE:MED) – Analysts at Zacks Research lowered their Q2 2025 EPS estimates for shares of Medifast in a report released on Monday, March 10th. Zacks Research analyst R. Department now expects that the specialty retailer will earn $0.24 per share for the quarter, down from their previous estimate of $0.29. The consensus estimate for Medifast’s current full-year earnings is $0.51 per share. Zacks Research also issued estimates for Medifast’s Q3 2025 earnings at $0.33 EPS, Q1 2026 earnings at $0.32 EPS, Q2 2026 earnings at $0.32 EPS, FY2026 earnings at $1.52 EPS and FY2027 earnings at $2.08 EPS.

Separately, DA Davidson decreased their price target on shares of Medifast from $17.00 to $16.50 and set a “neutral” rating on the stock in a research note on Wednesday, February 19th.

Medifast Stock Down 1.9 %

Shares of NYSE MED opened at $14.06 on Wednesday. The company’s 50-day simple moving average is $15.32 and its 200-day simple moving average is $17.45. Medifast has a 52-week low of $13.57 and a 52-week high of $39.14. The firm has a market cap of $153.79 million, a price-to-earnings ratio of 78.11 and a beta of 1.13.

Medifast (NYSE:MED) last issued its quarterly earnings results on Tuesday, February 18th. The specialty retailer reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.16) by $0.26. The company had revenue of $119.00 million for the quarter, compared to the consensus estimate of $114.25 million. Medifast had a net margin of 0.35% and a return on equity of 10.64%.

Institutional Investors Weigh In On Medifast

Institutional investors have recently made changes to their positions in the stock. Federated Hermes Inc. grew its holdings in shares of Medifast by 28.8% in the fourth quarter. Federated Hermes Inc. now owns 279,473 shares of the specialty retailer’s stock valued at $4,924,000 after purchasing an additional 62,574 shares in the last quarter. Geode Capital Management LLC grew its holdings in Medifast by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 245,929 shares of the specialty retailer’s stock worth $4,335,000 after acquiring an additional 1,447 shares in the last quarter. American Century Companies Inc. grew its holdings in Medifast by 3.4% during the 4th quarter. American Century Companies Inc. now owns 244,185 shares of the specialty retailer’s stock worth $4,303,000 after acquiring an additional 8,058 shares in the last quarter. Two Sigma Investments LP grew its holdings in Medifast by 11.4% during the 4th quarter. Two Sigma Investments LP now owns 232,069 shares of the specialty retailer’s stock worth $4,089,000 after acquiring an additional 23,822 shares in the last quarter. Finally, Two Sigma Advisers LP grew its holdings in Medifast by 86.0% during the 4th quarter. Two Sigma Advisers LP now owns 216,000 shares of the specialty retailer’s stock worth $3,806,000 after acquiring an additional 99,900 shares in the last quarter. 95.51% of the stock is currently owned by institutional investors and hedge funds.

About Medifast

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.